Zum Inhalt springen

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Dermatol Reports. 2025 Feb 6;17(1). doi: 10.4081/dr.2024.9999. Epub 2024 Aug 9.

ABSTRACT

Psoriasis is an inflammatory chronic disease of the skin, typically located on the extensor surfaces of the body and the trunk. Patients with psoriasis can often present multiple characteristics, such as lesions located in difficult-to-treat (DTT) areas or high severity of the disease, which can negatively affect their quality of life. There is a lack of consensus in identifying the best therapy for these complex patient populations, especially after the failure of one or multiple lines of therapy. In this regard, we report a case series describing patients with psoriasis located in different DTT areas or presenting a high Psoriasis Area and Severity Index (PASI) score at baseline and treated ineffectively with prior lines of therapy. Finally, patients achieved complete remission following therapy with tildrakizumab 200 mg (anti-IL-23p19), highlighting its potential efficacy in these patient populations.

PMID:40047295 | DOI:10.4081/dr.2024.9999

Den ganzen Artikel lesen


Was du hier liest, ist automatisch hierhergelangt. Die Seite dient uns als Überblick über das, was rund um die Schuppenflechte im Netz passiert – und als "Experimentierkasten".
Die volle Packung gibt es im Psoriasis-Netz. Es gilt auch das dortige Impressum.
Powered by Invision Community